Somewhat Positive Press Coverage Somewhat Unlikely to Impact Synopsys (SNPS) Stock Price

News coverage about Synopsys (NASDAQ:SNPS) has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Synopsys earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the semiconductor company an impact score of 45.7305446981815 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

SNPS has been the topic of a number of recent research reports. JPMorgan Chase downgraded shares of Synopsys from a “neutral” rating to an “underweight” rating and set a $87.00 price target on the stock. in a research note on Tuesday, December 12th. BidaskClub downgraded shares of Synopsys from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. KeyCorp reiterated an “overweight” rating and set a $110.00 price target (up previously from $106.00) on shares of Synopsys in a research note on Thursday, February 22nd. Zacks Investment Research downgraded shares of Synopsys from a “hold” rating to a “strong sell” rating in a research note on Monday, February 26th. Finally, Royal Bank of Canada restated a “buy” rating on shares of Synopsys in a research note on Friday, February 23rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $97.33.

Shares of NASDAQ:SNPS traded down $1.57 on Friday, hitting $81.39. The stock had a trading volume of 1,206,955 shares, compared to its average volume of 842,684. Synopsys has a twelve month low of $70.55 and a twelve month high of $94.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.68 and a current ratio of 0.68. The company has a market capitalization of $12,338.23, a PE ratio of 92.49, a P/E/G ratio of 5.34 and a beta of 1.09.

Synopsys (NASDAQ:SNPS) last issued its earnings results on Wednesday, February 21st. The semiconductor company reported $1.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.00 by $0.10. Synopsys had a net margin of 1.63% and a return on equity of 6.72%. The company had revenue of $769.40 million for the quarter, compared to the consensus estimate of $750.43 million. During the same quarter in the previous year, the company earned $0.94 EPS. The firm’s revenue for the quarter was up 17.9% compared to the same quarter last year. analysts forecast that Synopsys will post 1.55 EPS for the current year.

In other news, Director Steven Walske sold 4,545 shares of the business’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $90.12, for a total value of $409,595.40. Following the sale, the director now owns 14,988 shares in the company, valued at approximately $1,350,718.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Logan sold 10,313 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $84.69, for a total transaction of $873,407.97. Following the completion of the sale, the executive vice president now owns 78,584 shares in the company, valued at approximately $6,655,278.96. The disclosure for this sale can be found here. Insiders sold a total of 29,245 shares of company stock worth $2,529,005 in the last 90 days. 1.84% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3339353/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-synopsys-snps-stock-price.html.

About Synopsys

Synopsys, Inc provides electronic design automation (EDA) software products used to design and test integrated circuits (ICs). It offers Galaxy Design platform that offers IC design solutions; Verification Continuum Platform, which provides virtual prototyping, static and formal verification, simulation, emulation, field-programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.

Insider Buying and Selling by Quarter for Synopsys (NASDAQ:SNPS)

Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

NovoCure  Insider Sells $1,042,302.80 in Stock
NovoCure Insider Sells $1,042,302.80 in Stock
R. Hewitt Pate Sells 25,500 Shares of Chevron Co.  Stock
R. Hewitt Pate Sells 25,500 Shares of Chevron Co. Stock
Grimcoin Trading Up 33.5% This Week
Grimcoin Trading Up 33.5% This Week
Lazaruscoin  Price Tops $0.0009 on Major Exchanges
Lazaruscoin Price Tops $0.0009 on Major Exchanges
8X8  Coverage Initiated by Analysts at CIBC
8X8 Coverage Initiated by Analysts at CIBC
Conatus Pharmaceuticals  Reaches New 1-Year High and Low at $3.46
Conatus Pharmaceuticals Reaches New 1-Year High and Low at $3.46


Leave a Reply

© 2006-2018 Ticker Report. Google+.